Branchburg, NJ, United States of America

Paul Kurtulik


 

Average Co-Inventor Count = 4.7

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Somerset, NJ (US) (2015 - 2017)
  • Branchburg, NJ (US) (2017 - 2018)

Company Filing History:


Years Active: 2015-2018

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Paul Kurtulik: Innovator in Pharmaceutical Compositions

Introduction

Paul Kurtulik is a notable inventor based in Branchburg, NJ (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 4 patents. His work focuses on innovative formulations that aim to treat various medical conditions.

Latest Patents

Kurtulik's latest patents include formulations of cyclopropanecarboxylic acid, specifically the compound {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide. These patents detail pharmaceutical compositions and single unit dosage forms that are designed to manage or prevent disorders such as cancer and inflammatory diseases. Additionally, he has developed controlled release oral dosage forms of poorly soluble drugs, along with methods for their production and application in treating various diseases.

Career Highlights

Kurtulik is currently employed at Celgene Corporation, where he continues to advance his research and development efforts in the pharmaceutical industry. His innovative approaches have contributed to the creation of effective treatment options for patients.

Collaborations

Throughout his career, Kurtulik has collaborated with esteemed colleagues, including Ho-Wah Hui and Ming J Chen. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking pharmaceutical solutions.

Conclusion

Paul Kurtulik's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through effective treatments. His work continues to impact the industry positively, paving the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…